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Activation of mast cells (MCs) can be achieved by the high-affinity receptor for IgE (FcεRI) as well as by additional
receptors such as the lipopolysaccharide (LPS) receptor and the receptor tyrosine kinase Kit (stem cell factor [SCF]
receptor). Thus, pharmacological interventions which stabilize MCs in response to different receptors would be
preferable in diseases with pathological systemic MC activation such as systemic mastocytosis. 1,4-Benzodiazepines
(BDZs) have been reported to suppress MC effector functions. In the present study, our aim was to analyze
molecularly the effects of BDZs on MC activation by comparison of the effects of the two BDZs Ro5-4864 and
clonazepam, which markedly differ in their affinities for the archetypical BDZ recognition sites, i.e., the GABAA
receptor and TSPO (previously termed peripheral-type BDZ receptor). Ro5-4864 is a selective agonist at TSPO,
whereas clonazepam is a selective agonist at the GABAA receptor. Ro5-4864 suppressed pro-inflammatory MC
effector functions in response to antigen (Ag) (degranulation/cytokine production) and LPS and SCF (cytokine
production), whereas clonazepam was inactive. Signaling pathway analyses revealed inhibitory effects of Ro5-4864
on Ag-triggered production of reactive oxygen species, calcium mobilization and activation of different
downstream kinases. The initial activation of Src family kinases was attenuated by Ro5-4864 offering a molecular
explanation for the observed impacts on various downstream signaling elements. In conclusion, BDZs structurally
related to Ro5-4864 might serve as multifunctional MC stabilizers without the sedative effect of GABAA receptor-
interacting BDZs.
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1,4-Benzodiazepines (BDZs) are clinically used as anxio-
lytic, hypnotic, anti-convulsive, and muscle relaxing
drugs [1-4]. BDZs are lipophilic and readily cross cell
membranes. There are two major types of BDZ recogni-
tion sites. The first site is part of the GABAA receptor
complex found in cells of the central nervous system [5]
and, hence, is termed central-type BDZ receptor. The
other one is an ubiquitously expressed transmembrane
protein of the outer mitochondrial membrane (OMM)
termed translocator protein (18 kDa) (TSPO) [6]
(previously named peripheral-type BDZ receptor [7]).* Correspondence: mhuber@ukaachen.de
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reproduction in any medium, provided the orInteraction studies revealed that TSPO is associated with
the OMM protein voltage-dependent anion channel
(VDAC) and the inner mitochondrial membrane (IMM)
protein adenine nucleotide transporter (ANT) [8] and the
requirement for both TSPO and VDAC for BDZ binding
has been suggested. Most BDZs clinically used possess
nanomolar affinity for the central-type receptor, but only
milli- to micromolar affinities for TSPO. However, there
are also BDZs available with high affinity and selectivity
for TSPO (e.g. Ro5-4864 = 4-chlorodiazepam) [9], thus,
allowing the analysis of the potential involvement of
TSPO function in biological processes.
Expression of TSPO has also been described in mast cells
(MCs) [10-12]. MCs are hematopoietic, tissue-resident
cells, which are involved in various physiological as well as
pathophysiological scenarios. They are very importantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Yousefi et al. Cell Communication and Signaling 2013, 11:13 Page 2 of 15
http://www.biosignaling.com/content/11/1/13players in innate and adaptive immune responses, inflam-
mation, and tissue changes [13,14]. Important reactions
during these processes are allergen-triggered degranulation
of preformed mediators (e.g. histamine and proteases)
and lipopolysaccharide (LPS)-induced production of pro-
inflammatory cytokines (e.g. IL-6 and TNF-α), respect-
ively. In addition to the allergy-relevant high-affinity
receptor for IgE (FcεRI) and the LPS receptor (TLR4), the
receptor tyrosine kinase Kit represents another important
signaling system, which regulates MC differentiation,
proliferation, survival, chemotaxis, and production of
pro-inflammatory cytokines [15].
BDZs have been reported to inhibit MC effector
functions: Midazolam suppressed substance P-induced
chemotaxis as well as degranulation [16] of canine MCs.
Diazepam and midazolam inhibited proliferation of mur-
ine MCs as well as pro-inflammatory mediator release
from these cells [17]. With respect to systemic MC acti-
vation disease (MCAD) [17,18], the clinical efficacy of
the BDZs flunitrazepam, diazepam, bromazepam, and
midazolam for the treatment of MC mediator-induced
symptoms has been reported [18,19]. The TSPO-selective
BDZ Ro5-4864 was shown to inhibit concanavalin A-
induced serotonin release from as well as 45Ca uptake into
rat MCs, whereas the GABAA-receptor-selective BDZ
clonazepam only had a slight impact on serotonin release
and did not affect 45Ca uptake [11]. In addition, diazepam,
Ro5-4864, and flunitrazepam were demonstrated to re-
duce NECA-induced IL-8 production in human MC
leukemia cells [20]. Since on the one hand MCs did not
express GABAA receptors in previous investigations and
on the other hand most BDZs, such as flunitrazepam, di-
azepam, and midazolam possess considerable affinity for
TSPO [7,9,12], it was conceivable that the inhibitory
effects of BDZs on MCs may be due to their binding to
TSPO in MCs. In this context the aim of the present study
was to analyze the molecular processes underlying the
inhibitory action of BDZs in MCs by using two selective
BDZs: Ro5-4864 (4-chlorodiazepam) that possesses high
affinity for TSPO but has only low affinity for GABAA
receptors and clonazepam, a high-affinity ligand for
GABAA receptors with only low affinity for TSPO [12].
We show here that Ro5-4864 but not clonazepam
inhibited antigen (Ag)-triggered degranulation as well as
Ag-, LPS- or SF-induced pro-inflammatory cytokine pro-
duction. In addition, Ro5-4864 inhibited allergen-
induced bronchoconstriction in precision-cut lung slices.
Moreover, Ag-triggered Ca2+ mobilization and produc-
tion of reactive oxygen species (ROS) were suppressed
by Ro5-4864. By expressing a fluorescent TSPO fusion
protein and using confocal microscopy, we were not able
to detect a plasmalemnal localization of the TSPO-
containing fusion protein in MCs which has been
observed previously in some other cell types [21,22].Analysis of early Ag-triggered signaling events suggested
Ro5-4864-dependent attenuation of Src family kinases
(SFKs), which represent very early signaling molecules ac-
tive in the chain of FcεRI signaling. Hence, attenuation of
SFKs by direct inhibition and/or indirectly by targeting a
so far unidentified upstream plasmalemnal recognition
site could be the reason for the observed suppression of
pro-inflammatory MC responses.
Results
Ro5-4864 inhibits mast cell degranulation
IgE-loaded BMMCs were stimulated with Ag (DNP-HSA)
in the presence of vehicle (DMSO), Ro5-4864 or clo-
nazepam and degranulation was measured by means
of β-hexosaminidase assays. As shown in Figure 1A, Ro5-
4864 in a concentration-dependent manner inhibited Ag-
triggered degranulation, whereas clonazepam did not
show an effect different from the vehicle control. To verify
these data in a further MC model, PMCs were treated and
stimulated in a comparable fashion and degranulation was
measured. PMCs are an accepted model for serosal MCs
[23]. Again, clonazepam failed to decrease Ag-triggered
degranulation, whereas Ro5-4864 inhibited degranulation
in a concentration-dependent manner (Figure 1B). The ac-
tivity of IgE-loaded BMMCs and PMCs in the absence of
Ag as determined by spontaneous degranulation was not
influenced by the vehicle (DMSO), Ro5-4864 or clo-
nazepam (Figure 1A and B). Next, the effect of Ro5-4864
on allergen-induced bronchoconstriction in rat lung slices
was investigated. Lung slices have an intact microanatomy
and represent whole lung function in a reproducible way
[24]. In precision-cut lung slices, which were pretreated
with serum from sensitized animals, allergen-induced
bronchoconstriction was inhibited by Ro5-4864 in a
concentration-dependent manner (Figure 1C). These data
suggest that Ag-triggered MC activation can be sup-
pressed by Ro5-4864.
Ro5-4864 suppresses Ag-triggered Ca2+ influx as well as
ROS production
It is well known that Ca2+ influx is mandatory for a
degranulation reaction to occur [25]. Furthermore, pro-
duction of reactive oxygen species (ROS) has been
demonstrated to be important for Ag-triggered degranu-
lation [26,27]. The following Ca2+flux and ROS mea-
surements were carried out by means of flow cytometry.
Due to the respective processing of the cells it was
desirable to keep the pretreatment time with BDZs as
short as possible. Thus, the shortest effective incubation
time with Ro5-4864 to suppress MC degranulation was
determined. As shown in Figure 2A, a pretreatment time
even as short as 1 min resulted in complete inhibi-
tion of Ag-triggered MC degranulation by Ro5-4864.
Consequently, BDZ treatment for Ca2+ flux and ROS
Figure 1 Ro5-4864 inhibits MC degranulation. (A) IgE-loaded BMMCs were pretreated for 20 min with the indicated concentrations of BDZs
(Ro5-4864 and clonazepam) or a corresponding amount of DMSO and then either stimulated (white bars) with 20 ng/ml Ag (DNP-HSA) or left
unstimulated (black bars) for another 20 min. Degranulation was measured by β-hexosaminidase assay. Each bar is the mean of duplicates ± SEM.
Comparable results were obtained with cells from different cultures (n≥3). (B) IgE-loaded PMCs were treated as in (A) and degranulation was
measured. Each bar is the mean of duplicates ± SEM. Marks of significance (“asterisks”) relate to the respective vehicle (DMSO) control. Each
vehicle control contains the volume of DMSO necessary to dissolve the drugs in the respective BDZ samples. (C) Airway contractions to
ovalbumin in rat precision-cut lung slices. On the left upper image airway under control condition is shown, whereas in the left lower image the
airway has contracted to ovalbumin (10 μg/ml). On the right side kinetics of airway contractions to a single dose of OVA (10 μg/ml, n=5) in the
presence and absence of Ro5-4864 (10 μM, 30 μM and 100 μM) is shown. Contractions are expressed as the decrease of airway area (%)
compared to the initial airway area. Data (n=5) are presented as mean ± SEM. The area under the curve was compared by a one-way ANOVA
followed by a Dunnett-test for multiple comparisons. All Ro5-4864 concentrations showed a statistical significance compared to control.
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mobilization is a two step process comprising initial re-
lease of intracellular Ca2+ from the endoplasmic reticulum
(ER) via inositol-1,4,5-trisphosphate-gated Ca2+ channels
and subsequent influx of extracellular Ca2+ via store-
operated Ca2+ (SOC) channels [28]. BMMCs were pre-
treated with BDZs and stimulated with Ag in the presence
of the Ca2+ chelator EDTA to allow measurement ofrelease of intracellular Ca2+ only. As soon as the intracel-
lular Ca2+ concentration had returned to background
levels, CaCl2 was added to the cells to measure Ca
2+ influx
through opened SOC channels. Neither Ro5-4864 nor
clonazepam significantly influenced intracellular Ca2+
release (Figure 2B). However, Ro5-4864 concentration-
dependently attenuated the influx of extracellular Ca2+
(Figure 2B). Since in particular extracellular Ca2+ influx is
AB
C
BDZ
BDZ
Figure 2 Ro5-4864 suppresses Ag-triggered Ca2+ flux. (A) BMMCs were pretreated for the indicated times with 100 μM Ro5-4864 or for
30 min with a corresponding amount of DMSO and then either stimulated with Ag (DNP-HSA) (open symbols) or left unstimulated (solid
symbols) for another 10 min. Degranulation was measured by β-hexosaminidase assay. Each value is the mean of duplicates ± SEM. (B)
Intracellular Ca2+ was measured in BMMCs by flow cytometry using the Ca2+-sensitive fluorescent dyes fluo-3 and fura red. Steady-state
fluorescence was determined for 1 min before 1 mM EDTA (first arrow) was added for 1 min to chelate extracellular Ca2+. Denoted BZDs or
DMSO were added (second arrow) and incubated for 2 min. Cells were then stimulated with 200 ng/ml Ag (third arrow) and the resulting Ca2+
response derived from intracellular store depletion was measured for 3 min. Finally, 2 mM CaCl2 was added (fourth arrow) to replenish
extracellular Ca2+ stores and the resulting SOC influx was measured for 2 min. Comparable results were obtained with cells from different cultures
(n≥3). (C) Measurements were performed as described under (B) with the exception that cells were not stimulated with Ag, but with the SERCA
inhibitor thapsigargin (TG). Comparable results were obtained with cells from two different cultures.
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ate with Ro5-4864′s effect on degranulation. SOC
influx can also be triggered by thapsigargin, an inhibitor of
the sarcoplasmic-endoplasmic reticulum Ca2+ ATPase
(SERCA), which induces receptor-independent, passive
release of Ca2+ from the ER and thus triggers SOC influx
as well as degranulation [29]. Intriguingly, Ro5-4864 did
not suppress thapsigargin-induced Ca2+ influx, but even
slightly enhanced it (Figure 2C), suggesting that Ro5-4864
specifically influences an FcεRI-triggered signaling mech-
anism important for Ca2+ mobilization. It has been shown
previously that Ag-triggered SOC entry and degranulation
are dependent on intracellular ROS production [27]. In
agreement with our data on Ro5-4864 action, pretreat-
ment with Ro5-4864 inhibited Ag-induced ROS produc-
tion in a concentration-dependent manner (Figure 3). Incontrast, clonazepam did not influence Ag-triggered ROS
production (Figure 3).
Ro5-4864 suppresses pro-inflammatory cytokine
production in mast cells
Degranulation represents an immediate early response
to Ag stimulation taking place within the first minutes.
Another important pro-inflammatory response is the
production of cytokines (e.g. IL-6 and TNF-α), which is
a kinetically later event; significant amounts of produced
and secreted cytokines are measurable within 1.5 – 3 h
after Ag treatment. Moreover, pro-inflammatory cytokines
can also be produced in response to LPS and SCF, whereas
degranulation is a response particularly triggered by Ag.
Here, we sought to analyze the effects of Ro5-4864 and
clonazepam on pro-inflammatory cytokine production
BDZs
Figure 3 Ro5-4864 inhibits Ag-triggered ROS production. Intracellular ROS were measured in BMMCs by flow cytometry using the ROS-
sensitive fluorescent dye H2DCFDA. Background fluorescence was determined for 1 min before indicated BDZs or DMSO were added (first arrow)
and incubated for 2 min. Cells were then stimulated with 200 ng/ml Ag (second arrow) and the resulting intracellular ROS response was
measured for 3 min. Comparable results were obtained with cells from two different cultures.
Figure 4 Suppression of Ag-, LPS-, and SCF-triggered IL-6
production by Ro5-4864. IgE-loaded BMMCs were pretreated with
DMSO, Ro5-4864 or clonazepam for 20 min and subsequently
stimulated with 20 ng/ml Ag (A), 5 μg/ml LPS (B) or 150 ng/ml SCF
(C) for 3 h or left unstimulated. Subsequently, IL-6 concentrations in
the supernatants were determined by ELISA. Each bar is the mean of
triplicates ± SEM. Comparable results were obtained with cells from
different cultures (n≥3). Marks of significance (“asterisks”) relate to
the respective vehicle (DMSO) control.
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shown in Figure 4, Ro5-4864 inhibited production of IL-6
in a concentration-dependent manner in BMMCs sti-
mulated with Ag (Figure 4A), LPS (Figure 4B), and SCF
(Figure 4C). Although a certain suppression of IL-6 pro-
duction was found also in the presence of the highest
concentration (100 μM) of clonazepam, there was a
significant difference in efficiency between Ro5-4864
and clonazepam (Figure 4). A comparable pattern was
observed when investigating the effects of BDZs on pro-
duction of TNF-α in response to Ag (Figure 5A) and LPS
(Figure 5B). Thus, our data show that Ro5-4864, in con-
trast to clonazepam, is able to partially suppress pro-
inflammatory MC activation (degranulation and cytokine
production) in response to different ligand/receptor
systems.
Ro5-4864 attenuates activation of the PI3K pathway
Subsequently, we were interested in the molecular sig-
naling processes underlying the influence of Ro5-4864
on MC effector functions. It has been shown by others
and our laboratory that Ag-induced activation of the
PI3K pathway is crucial for degranulation [26,30]. There-
fore, we compared the effects of Ro5-4864 and
clonazepam on Ag-triggered phosphorylation of Akt at
S473, which is a well-known step in PI3K-dependent sig-
nal transduction. As shown in Figure 6A, correlating
with the effects on degranulation, Ro5-4864 pretreat-
ment did result in markedly reduced Akt phosphoryl-
ation, whereas such an effect was not observed with
clonazepam. A second protein of approximately 80 kDa
can be detected in MCs by the anti-P-Akt (S473) anti-
body. This represents ORP9 phosphorylated by PKC-β
at S287 [31]. The observed phosphorylation pattern
suggests that PKC-β activity is suppressed by Ro5-4864
treatment as well, whereas clonazepam has minimal ac-
tivity (Figure 6A). Interestingly, activation of the MEK-
Erk pathway (measured by detecting bis-phosphorylation
of Erk1/2 at T202/Y204) appeared to be less influenced
by Ro5-4864 treatment (Figure 6A), suggesting that Ro5-
4864 does not suppress MC activation in a generalized
Figure 5 Ro5-4864 inhibits TNF-α production in response to
Ag and LPS. IgE-loaded BMMCs were pretreated with DMSO,
Ro5-4864 or clonazepam for 20 min and subsequently stimulated
with 20 ng/ml Ag (A) or 5 μg/ml LPS (B) for 3 h or left
unstimulated. TNF-α concentrations in the supernatants were
determined by ELISA. Each bar is the mean of triplicates ± SEM.
Comparable results were obtained with cells from different cultures
(n≥3). Marks of significance (“stars”) relate to the respective vehicle
(DMSO) control.
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PI3K-mediated production of the second messenger
PIP3, the observed effect of Ro5-4864 treatment could in
part be due to attenuation of PI3K activation or to
enhanced activation of the PIP3 phosphatase SHIP1, the
prominent counter-player in MCs within the PI3K path-
way [32]. To address this, wild-type and SHIP1-deficient
BMMCs were stimulated with Ag in the presence of ve-
hicle or Ro5-4864 and S473 phosphorylation of Akt was
analyzed by Western blotting. In contrast to wild-type
cells, Ro5-4864 pretreatment did not affect Akt S473
phosphorylation in SHIP1-deficient BMMCs, suggesting
that the effect of Ro5-4864 was due to affecting SHIP1
activation rather than PI3K activation (Figure 6B). These
data suggested that Ro5-4864 should not be able to sup-
press Ag-triggered degranulation in SHIP1-deficient
BMMCs. Thus, SHIP1-deficient BMMCs were pre-
treated with vehicle or Ro5-4864 and degranulation in
response to Ag was measured. Unexpectedly, the inhibitoryeffect of Ro5-4864 was also observed in SHIP1-deficient
BMMCs (Figure 6C).
Interestingly, a comparable concentration-dependent
pattern was observed when analyzing the effect of Ro5-
4864 on Ag- or LPS-triggered IL-6 production in SHIP1-
deficient BMMCs (Figure 6D and Additional file 1: Figure
S1). Pro-inflammatory cytokine production downstream
of the FcεRI strongly depends on the NFκB as well as the
p38 MAPK pathways [33]. Whereas Ro5-4864 treatment
resulted in suppressed activation of p38 (measured by bis-
phosphorylation at T180/Y182) in response to Ag in wild-
type cells, no such effect was observed in SHIP1-deficient
BMMCs (Figure 6B). In addition, phosphorylation of IκBα
at S32 indicating activation of the NFκB pathway was
slightly attenuated by Ro5-4864 treatment in wild-type
BMMCs, which was not the case in SHIP1-deficient cells
(Figure 6B). These data suggest that Ro5-4864 suppresses
MC activation and effector functions independently of its
effect on the PI3K, p38, and/or NFκB pathways.
Ro5-4864 interferes with the tyrosine phosphorylation
response in mast cells
The comparative signaling data obtained in wild-type
and SHIP1-deficient BMMCs suggested that Ro5-4864
affects signaling events, which are activated independ-
ently of PI3K activation and/or SHIP1 presence. Protein
tyrosine phosphorylations represent the earliest signaling
events in response to Ag [34]. In this respect, BDZs were
found to have the potential to inhibit the tyrosine kinase
Src [35]. Moreover, the concentrations of Ro5-4864
needed for the observed inhibitory effects (10–100 μM)
appeared too high for a specific pharmacologic effect on
TSPO [36]. Since among the first kinases activated in re-
sponse to Ag are the SFKs Lyn and Fyn, we compared
the effect of Ro5-4864 on Ag-induced tyrosine phos-
phorylation events in wild-type and SHIP1-deficient
BMMCs. Indeed, in both wild-type and SHIP1-deficient
BMMCs Ro5-4864 pretreatment resulted in attenuation
of certain Ag-induced tyrosine phosphorylation events
(Figure 7A). Since this measurement is not target-
selective, we decided to specifically look at the tyrosine
phosphorylation status of the β-chain of the FcεRI, a
major Lyn target. A GST-fusion protein containing the
SH2-domain of Lyn can be used to pull down tyrosine-
phosphorylated FcεRIβ [37]. Thus, BMMCs were stim-
ulated with Ag in the presence or absence of Ro5-4864,
respective lysates were subjected to GST-SH2(Lyn) pull-
down, and interacting proteins were analyzed by anti-
phosphotyrosine immunoblotting. Corroborating the
data shown in Figure 7A, significantly less tyrosine-
phosphorylated proteins were pulled-down from lysates
of Ro5-4864-treated cells (Figure 7B). Amongst these,
two proteins of 35 kDa and 70 kDa were detected
(asterisks), most likely representing FcεRIβ and the
Figure 6 Ro5-4864 treatment attenuates activation of the PI3K pathway. (A) IgE-loaded BMMCs were pretreated for 20 min with 100 μM
Ro5-4864, 100 μM clonazepam or the respective amount of DMSO and stimulated with Ag (DNP-HSA, 20 ng/ml) for the indicated times or left
unstimulated. Subsequently, cellular lysates were analyzed by immunoblotting using antibodies against P-Akt (top panel), P-ERK1/2 (2nd panel
from top), P-IκBα (3rd panel from top), P-p38 (4th panel from top), and p85 (bottom panel, loading control). (B) IgE-loaded SHIP1+/+ and
SHIP1−/− BMMCs were pretreated for 20 min with 100 μM Ro5-4864 or DMSO and stimulated for the indicated times with 20 ng/ml Ag. Cellular
lysates were analyzed as described in (A). Comparable results were obtained with cells from different BMMC cultures. Densitometry was
performed and relative expression levels are indicated under each band. (C) IgE-loaded SHIP1-deficient BMMCs were pretreated for 20 min with
the indicated concentrations of Ro5-4864, clonazepam or a corresponding amount of DMSO and then either stimulated with 20 ng/ml Ag (DNP-
HSA) or left unstimulated for another 20 min. Degranulation was measured by β-hexosaminidase assay. Each bar is the mean of duplicates ± SEM.
Comparable results were obtained with cells from different cultures (n≥3). (D) IgE-loaded SHIP1-deficient BMMCs were pretreated for 20 min with
the indicated concentrations of Ro5-4864, clonazepam or a corresponding amount of DMSO and then stimulated with 20 ng/ml Ag or left
unstimulated for 3 h. IL-6 concentrations in the supernatants were determined by ELISA. Each bar is the mean of triplicates ± SEM. Comparable
results were obtained with cells from different cultures (n≥3). Marks of significance (“asterisks”) relate to the respective vehicle (DMSO) control.
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Figure 7 Ro5-4864 affects Ag-triggered tyrosine phosphorylation events in wild-type and SHIP1-deficient BMMCs. (A) IgE-loaded wild-
type and SHIP1-deficient BMMCs were pretreated for 20 min with 100 μM Ro5-4864 or the respective amount of DMSO and stimulated with Ag
(DNP-HSA, 20 ng/ml) for 5 min or left unstimulated. Subsequently, cellular lysates were analyzed by immunoblotting using antibodies against
phosphotyrosine (upper panel) and p85 (lower panel, loading control). (B) Wild-type BMMCs were treated as under (A) and cellular lysates were
subjected to pull-down reactions with GST or GST-SH2(Lyn) proteins. Precipitated proteins were analyzed by immunoblotting against
phosphotyrosine (top panel), Syk (middle panel), and FcεRIβ-chain (bottom panel). Usage of equal amounts of GST proteins was verified by
Coomassie staining (data not shown). Comparable results were obtained with cells from different BMMC cultures.
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found to be a Lyn target [38]. Reprobing the membrane
with anti-FcεRIβ and anti-Syk antibodies confirmed
reduced pull-down of these proteins with GST-SH2(Lyn)
from lysates of Ro5-4864-treated cells (Figure 7B), indi-
cating reduced tyrosine phosphorylation of these
proteins. The pull-down reactions were not directly
influenced by Ro5-4864 (data not shown). These data
suggest that Ro5-4864 is able to suppress tyrosine kinase
activity, most likely of SFKs, which might result in
attenuated Ag-triggered activation of MC effector
functions such as degranulation and pro-inflammatory
cytokine production.
TSPO is expressed in mitochondria of mast cells
The likely interference of Ro5-4864 with the SFK Lyn
does not entirely exclude a role for TSPO in MC activa-
tion. TSPO is mainly expressed in the OMM. However,
in particular cell types TSPO expression has also been
detected in the plasma membrane [21,22]. Since we
observed fast and marked inhibitory effects of Ro5-4864
treatment on various signaling events and effector
functions in MCs stimulated via different plasma mem-
brane receptor systems, we sought to address the
localization of TSPO in MCs by means of heterologous
expression of a fluorescent TSPO fusion protein and
confocal microscopy. Plasma membrane localization of
TSPO could hint at direct interference with plasma
membrane-resident receptors. A C-terminal eGFP fusionprotein with TSPO was constructed, expressed in RBL-
2H3 MCs or BMMCs and detected by confocal micros-
copy. Figure 8 displays in addition to a brightfield image
of the RBL-2H3 cells (C) the signal from TSPO-eGFP
(A), MitoTracker (B) and merge (D & E). The confocal
images showed clearly that TSPO localizes to the mito-
chondria of RBL-2H3 cells. TSPO could not be detected
in the plasma membrane. A TSPO-eGFP signal was ab-
sent in the plasma membrane even under the use of
much higher laser intensities (data not shown).
Compared to TSPO-eGFP, the eGFP control stained the
cytoplasm evenly as expected (data not shown). The
evaluation of TSPO-eGFP and mitochondria co-
localization in BMMCs displayed similar results to RBL-
2H3 cells. BMMCs are generally more difficult to
examine under the microscope because they are sub-
stantially smaller than RBL-2H3 cells, are not adherent,
and usually contain only little cytoplasm due to the con-
siderable amount of space occupied by secretory granules
and the nucleus. Nevertheless, colocalization of TSPO-
eGFP and mitochondria was observed in BMMCs. As for
RBL-2H3 cells, plasma membrane-resident TSPO could
be excluded (Additional file 2: Figure S2). Interestingly, in
all cells examined mitochondria appeared concentrated in
a perinuclear region.
Discussion
In the present study, our aim was to analyze molecularly
the inhibitory effect of BDZs on MC activity by
Figure 8 Subcellular localization of TSPO-eGFP in RBL-2H3 cells. RBL-2H3 cells were transiently transfected with TSPO-eGFP and stained with
MitoTracker Red CMXRos. TSPO-eGFP (A) and MitoTracker (B) fluorescence were detected approximately 48 h after transfection. Resulting signals
were analyzed and merged (D) with Zeiss ZEN 2009 software. Brightfield images (C) of the cells were added for reference. White bars (upper
right corner) equal 20 μm. Similar results were obtained for at least 10 different cells from 3 independent experiments. (E) Image magnification of
(D) showing one of the central cells to enable better visual analysis of the plasmalemnal area.
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and clonazepam. The two drugs differ markedly in their
affinities for the archetypical BDZ recognition sites, i.e.,
the GABAA receptor and the TSPO, previously termed
peripheral-type BDZ receptor. Ro5-4864 is an agonist at
TSPO and has only low affinity to the GABAA receptor
[39], whereas clonazepam is a high-affinity GABAA
receptor agonist, but has only low affinity for TSPO
[12]. Ro5-4864 concentration-dependently inhibited Ag-
triggered degranulation in BMMCs and PMCs, whereas
clonazepam was essentially ineffective in this respect. In
accordance with this observation, Ro5-4864 suppressed
Ca2+ mobilization, production of ROS and activation of
the PI3K pathway (as measured by phosphorylation of
Akt at Ser473), which are all important signaling events
in the positive regulation of the secretory response
[26,27]. These data suggest that Ro5-4864 and structur-
ally related compounds might be applicable as versatile
MC stabilizing drugs in MC-dependent diseases, e.g.,
hypersensitivity diseases, asthma, and systemic MCAD
[18,40]. This was also shown by the inhibition of
allergen-induced bronchoconstriction in rat precision-
cut lung slices. In this context it is interesting to note
that Ro5-4864 did not change the basal activation of the
MCs indicating a selective action of BDZs at (patho-
logically) activated MCs.
The question arises for the target sites at which Ro5-
4864 and other 1,4-benzodiazepines mediate their in-
hibitory effects on MCs. Since the selective GABAA
receptor agonist clonazepam did not mimic the effects
of Ro5-4864, an action of Ro5-4864 at classical GABAA
receptors is rather unlikely. One potential candidate
structure is TSPO, a transmembrane protein located in
the OMM and enriched in OMM-IMM contact sites. It
is a central component of a multimeric protein complex,
comprising amongst others TSPO, VDAC1, ANT, and
PRAX-1, and is associated with the mitochondrial perme-
ability transition pore (mPTP) [6]. Therefore, functions of
TSPO in regulating apoptotic processes have been
discussed. Indeed, Ro5-4864 has been reported to induce
apoptosis in some human and murine cancer cell lines
and thymocytes, in particular by interfering with the
mitochondrial membrane potential [41-45]. In these stud-
ies, cells were treated with Ro5-4864 for many hours to
days, i.e. for a much longer time span compared to our
experiments, which were performed within minutes to
3 h. The analysis of the effect of Ro5-4864 on BMMC
survival showed only subtle apoptotic effects after 24 h
(data not shown) excluding apoptotic effects within the
significant shorter time windows of our MC activation
experiments. Since we were able to reduce the pre-
incubation time with Ro5-4864 to 1 min without loosing
inhibitory efficiency, a mechanism via plasma membrane-
located target sites instead of mitochondria-residentTSPO seems more likely. Interestingly, in certain cell types
TSPO expression has also been detected in the plasma
membrane [21,22]. By expressing a fluorescent TSPO
fusion protein and using confocal microscopy, however,
we were not able to detect the TSPO-containing fusion
protein in the plasma membrane of MCs. Though we con-
sider the technique used sufficiently sensitive, we did not
have the material to detect endogenous TSPO and, thus,
cannot totally exclude expression of the endogenous
protein in the plasma membrane.
The concentration-dependent inhibition of Ag-triggered
degranulation by Ro5-4864 could be due to suppression of
mitochondrial Ca2+ uptake. Ag-triggered degranulation is
dependent on influx of extracellular Ca2+ ions through
SOC channels [46,47]. We found that Ro5-4864 sup-
pressed SOC entry, whereas intracellular Ca2+ release
from the ER appeared unaltered. Recently, Farsky and
colleagues reported on a similar attenuation of fMLP-
induced Ca2+ mobilization in neutrophils by Ro5-4864
[48]. Optimal SOC entry requires efficient emptying of the
ER. To prevent immediate re-uptake of Ca2+ into the ER
via the SERCA, mitochondria are able to take up Ca2+ at
the moment of release from the ER by the uniporter chan-
nel. Ro5-4864 treatment might suppress this mitochon-
drial Ca2+ uptake mechanism. If so, passive release of Ca2+
from the ER by means of treatment with the SERCA in-
hibitor thapsigargin should be independent of such a
mitochondrial buffering mechanism. Indeed, thapsigargin-
induced SOC influx was not suppressed by Ro5-4864
treatment, which would be in agreement with this
idea of an interaction of Ro5-4864 with mitochondrial
Ca2+ uptake.
However, the effects of Ro5-4864 on Ag-triggered sig-
naling in BMMCs deficient for the negative regulator
SHIP1 point to another target site of Ro5-4864. Intri-
guingly, whereas Ro5-4864 concentration-dependently
suppressed degranulation in SHIP1-deficient BMMCs,
Ag-triggered activation of Akt was not altered in these
cells. Moreover, there was only a slight reduction of
extracellular Ca2+ influx (Additional file 3: Figure S3). It
is known that SHIP1-deficient MCs are less sensitive to
drugs inhibiting PI3K compared to wild-type MCs [49].
Since Akt phosphorylation and Ca2+ mobilization are
PI3K-dependent [26,49] suppression of PI3K activation
by Ro5-4864 was not as effective in SHIP1-deficient
BMMCs. These data suggested that Ro5-4864 very likely
did not interfere with the mitochondrial Ca2+ buffering
mechanism (such an effect should be observable in
SHIP1-deficient BMMCs as well) and that a target site
located more upstream should be involved in Ro5-4864-
mediated regulation of the secretory response.
1,4-Benzodiazepines have been reported to inhibit
SFKs [35], which are known to play multiple important
roles in MC activation, in particular via the FcεRI [50].
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FcεRI crosslinking are activation of the SFK Lyn, subse-
quent tyrosine phosphorylation of the FcεRI β-chain and
γ-chain ITAMs by Lyn and activation of the tyrosine kin-
ase Syk via interaction with the phosphorylated γ-chains
and phosphorylation by Lyn [34]. Moreover, immediate
activation of the SFK Fyn leads to the activation of the
PI3K pathway [51]. Thus, pharmacological interference
with SFK activation would have a negative impact on most
FcεRI-mediated signaling pathways. Indeed, Ro5-4864
attenuated Ag-triggered tyrosine phosphorylation events
in both wild-type and SHIP1-deficient MCs. Using a GST-
SH2(Lyn) fusion protein to pull-down specific tyrosine-
phosphorylated proteins, reduced phosphorylation of
FcεRIβ and Syk was observed, indicating early interference
of FcεRI signaling by Ro5-4864. Though both FcεRIβ and
Syk are known targets of Lyn, involvement of other SFKs
cannot be excluded, all the more since particularly Fyn
seems involved in regulation of Ag-triggered degranula-
tion and activation of the PI3K pathway [51]. In this
respect, enhanced Ag-induced phosphorylation of Akt in
Lyn-deficient BMMCs was markedly suppressed by Ro5-
4864, clearly indicating Lyn-independent effects of this
BDZ and suggesting a Fyn-dependent effect (Additional
file 4: Figure S4).
Whereas degranulation is a fast response after Ag
triggering of MCs occurring within a few minutes,
production of pro-inflammatory cytokines takes place
with slower kinetics. Important signaling pathways for
cytokine production downstream of the FcεRI include
the PI3K, p38, and NFκB pathways [33]. All of these
pathways were attenuated by Ro5-4864 treatment in
wild-type MCs underlining the role of central signaling
elements, e.g. SFKs, being blocked by this drug. Intri-
guingly, Ro5-4864 also concentration-dependently sup-
pressed cytokine production in response to stimulation
of receptor systems such as Kit and TLR4. Also this ef-
fect can be explained by the inhibition of SFKs. Both
Lyn and Fyn have been reported to play positive regula-
tory roles in the context of Kit signaling [52,53]. In
addition, a recent publication by Avila et al. has
demonstrated the importance of Lyn for the production
of TNF-α in response to LPS in MCs [54]. Thus,
all effects observed in the present study with the 1,4-
benzodiazepine Ro5-4864 are explainable by attenuation
of SFK activity.
Conclusions
In conclusion, the present data demonstrate that the
1,4-benzodiazepine Ro5-4864 significantly suppresses
pro-inflammatory MC responses downstream of differ-
ential ligand/receptor systems, most likely by attenuating
SFK activity by direct inhibition of the respective SFK
and/or indirectly by acting at a so far unknownupstream plasmalemnal recognition site. Hence, Ro5-
4864 and structurally related compounds might be
applicable as effective MC stabilizing drugs in different
MC-dependent diseases, such as allergies, asthma, and
systemic MCAD. It is however mandatory to identify and
characterize the direct molecular target(s) to exclude un-
wanted side effects on other immune and non-immune
cells. For certain MC-dependent diseases, however, topical
administration as cream, eye drops or nasal spray could be
options for first applications.
Material and methods
Chemicals
Ro5-4864, clonazepam, DNP-HSA (containing 30–40
mol DNP per mole albumin), monoclonal IgE anti-DNP
(SPE-7), ovalbumin, thapsigargin, and EDTA were
purchased from Sigma-Aldrich, Munich, Germany. Fluo-
3 AM, Fura Red AM, pluronic F-127, H2DCFDA,
MitoTracker Red CMXRos, and recombinant mouse SCF
were obtained from (Invitrogen, Karlsruhe, Germany).
Monoclonal mouse anti-P-Akt (S473), monoclonal
rabbit anti-P-Erk1/2 (T202/Y204), polyclonal rabbit
anti-P-IκBαS32, and polyclonal rabbit anti-P-p38
(T180/Y182) antibodies were purchased from Cell Sig-
naling Technology, Frankfurt, Germany, polyclonal rabbit
anti-p85 from Millipore, Schwalbach, Germany, polyclonal
anti-Syk antibody (N-19) from Santa Cruz Biotechnology,
and DMSO from AppliChem, Darmstadt, Germany.
Monoclonal anti-FcεRIβ antibody was kindly provided by
Dr. R. Siraganian (Bethesda, MD). R-form LPS from S.
Minnesota mutant R595 was extracted and purified as
described [55-57] and was a gift from Dr. M. Freudenberg
and Dr. C. Galanos (MPI for Immunobiology and Epigen-
etics, Freiburg, Germany).
Cell culture
Bone marrow-derived MCs (BMMCs): According to the
technique established by Razin et al. [58], bone marrow
cells (1×106/ml) from 6 to 8 week old mice (129/Sv ×
C57BL/6) were cultured (37°C, 5% CO2) as single cell
suspensions in RPMI 1640 medium supplemented with
15% FCS, 1% X63Ag8-653-conditioned medium (source of
IL-3 [59]), 2 mM L-glutamine, 10 μM β-mercaptoethanol,
50 units/ml penicillin, and 50 mg/ml streptomycin. At
weekly intervals, the non-adherent cells were reseeded at
5×105 cells/ml in fresh medium. After 4–6 weeks in
culture, greater than 99% of the cells were Kit and FcεRI
positive as assessed by FACS using phycoerythrin-labeled
anti-c-kit antibodies (Pharmingen, Mississauga, Canada)
and FITC-labeled hamster anti-mouse FcεRIα antibodies
(eBioscience, Frankfurt, Germany), respectively. SHIP1+/+
and −/− BMMCs as well as Lyn+/+ and Lyn−/− BMMCs
were differentiated in vitro using the same protocol
but starting from bone marrow cells of 6 to 8 week old
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Peritoneal MCs (PMCs) were cultivated according
to Malbec et al. [23]. RBL-2H3 cells were maintained
(37°C; 5% CO2) in RPMI 1640 medium supplemented
with 10% FCS, 2 mM L-glutamine, 50 units/ml penicillin,
50 mg/ml streptomycin, and 50 μM β-mercaptoethanol.
Cellular stimulation and western blotting
IgE-loaded BMMCs were washed in PBS and re-
suspended in RPMI/0.1% BSA. Cells were adapted to
37°C for 15 min and pretreated and stimulated as
indicated. After stimulation, cells were pelleted and
solubilized with 0.5% NP-40 and 0.5% sodium deo-
xycholate in 4°C phosphorylation solubilisation buffer
[60]. After normalizing for protein content, the post-
nuclear supernatants (obtained after centrifugation at
4°C at 13,200 rpm in an Eppendorf 4515R centrifuge
(F45-24-11 rotor) for 15 min) were subjected directly to
SDS-PAGE and Western blot analysis [60]. The GST-SH2
(Lyn) construct was described previously [61] and produc-
tion, pull-down and immunoblotting were performed as
published [62].
Degranulation assay
For degranulation studies, MCs were preloaded with
0.15 μg/ml IgE anti-DNP overnight at 37°C. The cells
were then washed and resuspended in Tyrode’s buffer
(130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 1 mM
MgCl2, 5.6 mM glucose, and 0.1% bovine serum albumin
(BSA) in 10 mM Hepes, pH 7.4). The cells were adapted
to 37°C for 20 min and then treated at 37°C as
mentioned. Vehicle (DMSO) and BDZ treatment was for
20 min prior to Ag (DNP-HSA) addition. The degree of
degranulation was determined by measuring the release
of β-hexosaminidase [63].
Preparation and use of precision-cut lung slices
Precision-cut lung slices (PCLS) were prepared from 8-
week-old Wistar rats (220 ± 20 g) obtained from Charles
River (Sulzfeld, Germany) and kept under controlled
conditions (22°C, 55% humidity and 12-h day/night
rhythm). Animal experiments were approved by the
local ethics committee. Rat PCLS were prepared as pre-
viously described [64]. Rats were sacrificed by an over-
dose of pentobarbital i.p. (60 mg/kg). Isolated lungs were
filled with pre-warmed agarose solution (0.75%) via the
trachea and subsequently chilled with ice. Then lobes
were separated and cut into 5 to 10 mm thick tissue
segments from which cores were made along the
airways, and then cut into 250 ± 20 μm thick slices
(Alabama Research and Development, Munford, AL).
For studies with ovalbumin, the lung slices were
incubated overnight with cell culture medium containing
1% serum from actively sensitized rats, as previouslydone [64]. After overnight culturing, the airways in
PCLS were imaged and digitized using a digital video
camera. A control picture was taken before addition of
DMSO or Ro5-4864 (10 μM, 30 μM, and 100 μM) and
after addition of ovalbumin (10 μg/ml) frames were
recorded every 30 s for 15 min. The images were
analyzed by the image analysis program Optimas 6.5
(Optimas, Bothell, WA).
IL-6/TNF-α ELISAs
Mouse IL-6 and TNF-α ELISAs (BD Pharmingen,
Heidelberg, Germany) were performed according to the
manufacturer’s instructions. Absolute levels of cytokines
in culture supernatants varied between experiments/
BMMC cultures. Qualitative differences, however, were
consistent throughout the study. Experiments were done
in triplicates and performed at least three times.
Measurement of Ca2+ mobilization
IgE-preloaded BMMCs were washed with RPMI 1640
medium, resuspended at 5 × 106 cells/ml in RPMI 1640
containing 1% FCS, 1.3 μM Fluo-3 AM, 2.7 μM Fura
Red AM, and 0.1% pluronic F-127, and incubated for
30 min at 37°C. Cells were then pelleted, resuspended in
RPMI 1640 containing 1% FCS and analyzed in a
FACSCalibur flow cytometer (BD Biosciences) after the
indicated stimulation procedures. The FACS profiles
were converted to line graph data using the FlowJo ana-
lysis software (Treestar, Ashland, OR, USA).
Flow cytometric analysis of ROS production
IgE-sensitized BMMCs were washed with PBS, re-
suspended in RPMI 1640/1% FCS (5 × 106 cells/ml), and
stained with the free radical-sensitive dye H2DCFDA
(final concentration: 10 μM) for 30 min at 37°C in the
dark. Subsequently, stimulus (antigen) was added and
flow cytometric analysis of cell samples was carried out
using a FACSCalibur (Beckton Dickinson, San Jose,
USA). Data were processed by FlowJo analysis software.
Molecular cloning and transfection
To obtain a fusion construct comprising murine TSPO
and an enhanced green fluorescent protein (eGFP), TSPO
cDNA at its 30-end was fused to eGFP sequence. Murine
TSPO full-length cDNA (FANTOM clone I830130P14)
was obtained from imaGenes GmbH (Berlin, Germany)
and plasmid pEGFP-N1 from Clontech Laboratories Inc
(Mountain View, USA). The coding sequence of TSPO
was inserted in-frame using EcoRI and BamHI restriction
sites resulting in pEGFP-N1-TSPO. The final plasmid was
controlled by DNA-sequencing. RBL-2H3 cells as well as
BMMCs were transiently transfected with pEGFP-N1-
TSPO via electroporation with the Neon Transfection
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according to the manufacturer’s instructions.
Fluorescence microscopy
RBL-2H3 cells were detached from the plate, reseeded on
cover slips in a 12-well plate and incubated for another
24 h. BMMCs (24 h post transfection) were transferred to
a 12-well plate containing cover slips pretreated with 0.1%
poly-L-lysine in PBS and were also incubated for further
24 h. 48 h after transfection, mitochondria of RBL-2H3
cells and BMMCs were stained with MitoTracker Red
CMXRos. Cells were incubated for 30 min at 37°C with
200 nM MitoTracker in stimulation medium. Cells were
then washed twice with PBS containing 9 mM CaCl2 and
5 mM MgCl2 and fixed with methanol for 20 min in the
dark at RT. Background fluorescence was then quenched
for 5 min with 50 mM NH4Cl in PBS containing 9 mM
CaCl2, 5 mM MgCl2, and 0.1% (v/v) Triton X 100 at RT.
Finally, cells were washed in water and mounted on a
glass slide with one drop of Immunomount. The prepared
slides were analyzed with a Zeiss LSM 710 (Carl Zeiss
AG, Jena, Germany) confocal laser scanning microscope.
All images were taken with a 63x oil immersion objective.
For the fluorophores, the following lasers, excitation
wavelengths, and detected range of emission wavelengths
were used: eGFP (Laser: Argon; Excitation Wavelength:
488 nm; detected wavelength range: 493–574 nm) and
MitoTracker Red CMXRos (Laser: DPSS 561–10; Excita-
tion Wavelength: 561 nm; Detected Wavelength Range:
568–691 nm). During all measurements, the pinhole was
set to 1 AU. The obtained images were analyzed with the
Zeiss ZEN 2009 software.
Statistical analysis
P values were calculated by the paired two-tailed Student’s
t test. P values of * < 0.05, ** < 0.005, and *** < 0.0005 were
considered statistically significant. ns, non-significant.
Additional files
Additional file 1: Figure S1. Suppression of LPS-induced IL-6
production in SHIP1-deficient BMMCs by Ro5-4864. SHIP1-deficient
BMMCs were pretreated with DMSO, Ro5-4864 or clonazepam for 20 min
and subsequently stimulated with 5 μg/ml LPS for 3 h or left
unstimulated. Subsequently, IL-6 concentrations in the supernatants were
determined by ELISA. Each bar is the mean of triplicates ± SEM.
Comparable results were obtained with cells from different cultures.
Marks of significance (“asterisks”) relate to the respective vehicle (DMSO)
control.
Additional file 2: Figure S2. Subcellular localization of TSPO-eGFP in
BMMCs. BMMCs were transiently transfected with TSPO-eGFP and stained
with MitoTracker Red CMXRos. TSPO-eGFP (A) and MitoTracker (B)
fluorescence were detected approximately 48 h after transfection.
Resulting signals were analysed and merged (D) with Zeiss ZEN 2009
software. A brightfield image (C) was added for reference. White bars
(lower left corner) equal 20 μm. Similar results were obtained for different
cells from independent experiments.Additional file 3: Figure S3. Effect of Ro5-4864 on antigen-triggered
Ca2+ flux in SHIP1-deficient BMMCs. Intracellular Ca2+ was measured in
SHIP1-deficient BMMCs by flow cytometry using the Ca2+-sensitive
fluorescent dyes fluo-3 and fura red. Steady-state fluorescence was
determined for 1 min before 1 mM EDTA (first arrow) was added for
1 min to chelate extracellular Ca2+. Ro5-4864 (100 μM) or DMSO were
added (second arrow) and incubated for 2 min. Cells were then
stimulated with 200 ng/ml Ag (third arrow) and the resulting Ca2+
response derived from intracellular store depletion was measured for
3 min. Finally, 2 mM CaCl2 was added (fourth arrow) to replenish
extracellular Ca2+ stores and the resulting SOC influx was measured for
2 min. Comparable results were obtained with cells from different cell
cultures.
Additional file 4: Figure S4. Ro5-4864 treatment attenuates activation
of the PI3K pathway in Lyn-deficient mast cells. IgE-loaded Lyn+/+ and
Lyn−/− BMMCs were pretreated for 20 min with 100 μM Ro5-4864 or the
respective amount of DMSO and stimulated with Ag (DNP-HSA, 20 ng/
ml) for 5 min or left unstimulated. Subsequently, cellular lysates were
analyzed by immunoblotting using antibodies against P-Akt (upper
panel) and p85 (lower panel, loading control).
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